Tove Henriksen

Dr. Tove Henriksen


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
RKRegina Katzenschlager
Regina Katzenschlager
WPWerner Poewe
Werner Poewe
OROlivier Rascol
Olivier Rascol
CTClaudia Trenkwalder
Claudia Trenkwalder
GDGünther Deuschl
Günther Deuschl
ALAndrew Lees
Andrew Lees
The randomized, double-blind phase (DBP) of the TOLEDO study confirmed the efficacy of apomorphine infusion (APO) in reducing OFF time in PD patients with persistent motor fluctuations despite optimized oral/transdermal therapy. Here we report safety and efficacy results including the 52-week open-label phase (OLP). All patients completing the 12-week DBP (including those switching early to open-label treatment) were offered OLP entry. The primary objective was the evaluation of long-term safety of APO. Eighty-four patients entered the OLP (40 previously on APO, 44 on placebo) and 59 patients (70.2%) completed the study. The safety profile of APO was consistent with experience from extensive clinical use. Common treatment-related adverse events (AEs) were mild or moderate infusion site nodules, somnolence and nausea. Fourteen (16.7%) patients discontinued the OLP due to AEs, those involving >1 patient were infusion site reactions (n = 4) and fatigue (n = 2); hemolytic anemia occurred in one case. Reduction in daily OFF time and improvement in ON time without troublesome dyskinesia were sustained for up to 64 weeks. Pooled data for week 64 (n = 55) showed a mean (SD) change from DBP baseline in daily OFF time of -3.66 (2.72) hours and in ON time without troublesome dyskinesia of 3.31 (3.12) hours. Mean (±SD) daily levodopa-equivalent dose decreased from DBP baseline to week 64 by 543 mg (±674) and levodopa dose by 273 mg (±515). The safety and efficacy of APO infusion were demonstrated with long-term use for persistent motor fluctuations, allowing substantial reductions in oral PD medication.

1 September 2023 in Journal of Neural Transmission
Verified
Journal Article
Open access
PDF file
THTove Henriksen
Tove Henriksen
RKRegina Katzenschlager
Regina Katzenschlager
RBRoongroji Bhidayasiri
Roongroji Bhidayasiri
HSHarry Staines
Harry Staines
DLDonna Lockhart
Donna Lockhart
ALAndrew Lees
Andrew Lees
Subcutaneous apomorphine infusion is a device-aided therapy for Parkinson’s disease that can be considered when motor fluctuations become persistent and are no longer adequately controlled by oral/transdermal medication. Apomorphine infusion is less invasive than enteral levodopa, deep brain stimulation or focused ultrasound, and is often indicated even when neurosurgical approaches are contraindicated. This article aims to provide practical guidance for doctors and nurses initiating and treating patients with apomorphine infusion, and is based on both trial data and clinical experience from movement disorders specialists. A post hoc analysis of data from the TOLEDO randomized clinical trial of apomorphine infusion was conducted along with an analysis of ‘real world’ experience from 13 movement disorders specialists using a questionnaire that focused on starting patients on apomorphine infusion. Practical guidelines for starting treatment with apomorphine infusion are provided taking into consideration the regional disparities in healthcare. Apomorphine infusion is straightforward to administer but to be successful it requires concordance from the patient and family, and clinical support from an experienced team of doctors and nurses, particularly in the early months of treatment.

Verified
Journal Article
Open access
PDF file
THTove Henriksen
Tove Henriksen
HSHarry Staines
Harry Staines
(1) Background: Subcutaneous apomorphine infusion (SCAI) is one of the three main treatment options for motor fluctuations in advanced Parkinson’s disease (PD). The adherence to SCAI is generally considered to be low due to adverse events and because it is perceived as a treatment option to be used for a limited period only. We evaluated the reasons for discontinuation of SCAI in relation to when patients stopped treatment. (2) Methods: We reviewed the medical records of PD patients treated with SCAI at a single center, capturing patient demographics and the reasons for cessation of SCAI. (3) Results: 101 patients were included in the analysis, with a median time on treatment of 6.34 years. The main reasons for stopping SCAI were adverse events, death, and dissatisfaction with treatment. In the first 6 years of treatment, the predominant side effects leading to discontinuation were somnolence and hallucinations. (4) Conclusions: We suggest that SCAI can be an effective long-term treatment option for advanced PD, but it requires careful patient selection, a high level of communication with the patient and carer, and rigorous monitoring of the effects of treatment and for any adverse events so they can be promptly managed.


1 January 2012 in European Neurological Review
Verified
Journal Article
Closed access
THTove Henriksen
Tove Henriksen
POPer Odin
Per Odin
JVJens Volkmann
Jens Volkmann
Angelo AntoniniAngelo Antonini
Angelo Antonini
There are many factors that may influence treatment choice in patients with Parkinson’s disease. While ‘inclusion’ criteria include the clinical need for short- and long-term improvement, there are some well defined contraindications to continuous dopaminergic stimulation (CDS) therapies, such as age, cognitive impairment, psychosis or severe orthostatic hypotension. These contraindications vary between CDS therapies and can help guide the choice of treatment. Patient preferences and the practicalities of the treatment modality also play an important part in the decision-making process. Treatment selection algorithms have been developed and presented, but they require refining and need to be expanded to include guidance on management decisions – for example, when initial CDS therapy fails. While more trial data are gathered and as management algorithms evolve, case studies continue to provide important information on practical aspects of CDS therapies.